UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 14, 2017

 


 

BEIGENE, LTD.

(Exact name of registrant as specified in its charter)

 


 

Cayman Islands

 

001-37686

 

98-1209416

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

 

c/o Mourant Ozannes Corporate Services (Cayman) Limited

94 Solaris Avenue, Camana Bay

Grand Cayman KY1-1108

Cayman Islands

(Address of principal executive offices) (Zip Code)

 

+1 (345) 949 4123

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   x

 

 

 



 

Item 8.01                                            Other Events

 

On June 14, 2017, BeiGene, Ltd. (the “Company”) issued a press release announcing updated clinical data from the ongoing Phase 1 trial of its Bruton’s Tyrosine Kinase (“BTK”) inhibitor BGB-3111 in patients with chronic lymphocytic leukemia (“CLL”) and small lymphocytic lymphoma (“SLL”) in a poster at the 14 th  International Conference on Malignant Lymphoma (“14-ICML”) in Lugano, Switzerland. The full text of the Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

On June 15, 2017, the Company issued a press release announcing updated data from the ongoing Phase 1 trial of its BTK inhibitor BGB-3111 in patients with Waldenström’s macroglobulinemia presented at 14-ICML. The full text of the Company’s press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

 

On June 16, 2017, the Company issued a press release announcing initial clinical data from the ongoing Phase 1 trial of its BTK inhibitor BGB-3111 combined with the anti-CD20 antibody obinutuzumab in patients with CLL or SLL and follicular lymphoma presented at 14-ICML. The full text of the Company’s press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01                                            Financial Statements and Exhibits

 

(d)               Exhibits.

 

Exhibit No.

 

Description

99.1

 

Press Release issued on June 14, 2017

99.2

 

Press Release issued on June 15, 2017

99.3

 

Press Release issued on June 16, 2017

 

*    *    *

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: June 16, 2017

BEIGENE, LTD.

 

 

 

 

 

 

 

By:

/s/ Scott A. Samuels

 

Name:

Scott A. Samuels

 

Title:

Senior Vice President, General Counsel

 

3



 

Exhibit Index

 

Exhibit No.

 

Description

99.1

 

Press Release issued on June 14, 2017

99.2

 

Press Release issued on June 15, 2017

99.3

 

Press Release issued on June 16, 2017

 

4


BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more BeiGene Charts.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more BeiGene Charts.